StockData
Harvard Bioscience Inc logo

Harvard Bioscience Inc (HBIO) stock

HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/3040% above fair value
$9.00−0.08 (-0.88%)

Close on Nov 18, 2026Market cap $40.97MP/E –Yield –

Harvard Bioscience operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Harvard Bioscience's operating income for the twelve months ending Jun 30, 2026 was -$245.00K. For fiscal 2025 it was -$48.58M. The highest annual figure on record is $10.22M in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.58M–
FY2024Dec 31, 2024-$6.21M-427.9%
FY2023Dec 31, 2023$1.89M–
FY2022Dec 31, 2022-$6.93M-435.6%
FY2021Dec 31, 2021$2.07M+834.8%
FY2020Dec 31, 2020$221.00K-41.4%
FY2019Dec 31, 2019$377.00K-61.7%
FY2018Dec 31, 2018$984.00K–
FY2017Dec 31, 2017-$635.00K–
FY2016Dec 31, 2016-$3.00M–
FY2015Dec 31, 2015-$1.71M-125.9%
FY2014Dec 31, 2014$6.62M+330.6%
FY2013Dec 31, 2013$1.54M-80.4%
FY2012Dec 31, 2012$7.83M-6.8%
FY2011Dec 31, 2011$8.41M-17.7%
FY2010Dec 31, 2010$10.22M+26.9%
FY2009Dec 31, 2009$8.06M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$978.00K–
Q1 FY2026Mar 31, 2026-$1.17M–
Q4 FY2025Dec 31, 2025$1.71M+15445.5%
Q3 FY2025Sep 30, 2025$197.00K–
Q2 FY2025Jun 30, 2025-$819.00K–
Q1 FY2025Mar 31, 2025-$49.67M–
Q4 FY2024Dec 31, 2024$11.00K-96.1%
Q3 FY2024Sep 30, 2024-$1.87M–
Q2 FY2024Jun 30, 2024-$2.07M-359.9%
Q1 FY2024Mar 31, 2024-$2.28M-230.3%
Q4 FY2023Dec 31, 2023$282.00K–
Q3 FY2023Sep 30, 2023-$933.00K–
Q2 FY2023Jun 30, 2023$796.00K-80.1%
Q1 FY2023Mar 31, 2023$1.75M–
Q4 FY2022Dec 31, 2022-$457.00K-126.9%
Q3 FY2022Sep 30, 2022-$3.76M-786.5%
Q2 FY2022Jun 30, 2022$4.00M+6793.1%
Q1 FY2022Mar 31, 2022-$6.71M–
Q4 FY2021Dec 31, 2021$1.70M-38.4%
Q3 FY2021Sep 30, 2021$548.00K+201.1%
Q2 FY2021Jun 30, 2021$58.00K-89.6%
Q1 FY2021Mar 31, 2021-$239.00K–
Q4 FY2020Dec 31, 2020$2.76M+68.8%
Q3 FY2020Sep 30, 2020$182.00K–
Q2 FY2020Jun 30, 2020$556.00K+143.9%
Q1 FY2020Mar 31, 2020-$3.27M–
Q4 FY2019Dec 31, 2019$1.63M-6.3%
Q3 FY2019Sep 30, 2019-$1.37M-253.4%
Q2 FY2019Jun 30, 2019$228.00K–
Q1 FY2019Mar 31, 2019-$120.00K–
Q4 FY2018Dec 31, 2018$1.74M+365.8%
Q3 FY2018Sep 30, 2018$890.00K–
Q2 FY2018Jun 30, 2018-$382.00K–
Q1 FY2018Mar 31, 2018-$1.27M–
Q4 FY2017Dec 31, 2017$374.00K–
Q3 FY2017Sep 30, 2017-$390.00K–
Q2 FY2017Jun 30, 2017-$269.00K–
Q1 FY2017Mar 31, 2017-$350.00K–
Q4 FY2016Dec 31, 2016-$1.12M–
Q3 FY2016Sep 30, 2016-$813.00K–

More Harvard Bioscience figures

See a number that looks wrong?